1192-21-8

Usage

InChI:InChI=1/C4H7N3/c1-7-3-2-4(5)6-7/h2-3H,1H3,(H2,5,6)

Upstream product

• 5334-41-8 5-amino-4-cyano-1-methylpyrazole 
• 871-29-4 trans-β-chloroacrylonitrile 
• 60-34-4 methylhydrazine 
• 6162-76-1 cyanoacetaldehyde 
• 60838-50-8 3-methoxy-2-propenenitrile 
• 50-00-0 formaldehyd 
• 107-13-1 acrylonitrile 
• 31037-02-2 ethyl 5-amino-1-methyl-1H-pyrazole-4-carboxylate 
• 54210-33-2 1-methyl-5-nitropyrazole 
• 1225387-53-0 3⁽⁵⁾-aminopyrazole 
• 74-88-4 methyl iodide 
• 128315-64-0 1-Methylaminopyrazole 

Downstream Products

• 116835-08-6 3,6-Dimethyl-1-(4-nitro-phenyl)-1H-pyrazolo[3,4-b]pyridine 
• 59026-62-9 1,6-dimethyl-1H-pyrazolo[3,4-b]pyridine 
• 118431-49-5 1-methyl-5-(2-nitrobenzylidene)aminopyrazole 
• 92388-29-9 methyl 4,7-dihydro-1,6-dimethyl-4-(2-nitrophenyl)pyrazolo<3,4-b>pyridine-5-carboxylate 
• 116855-20-0 (Z)-2-Cyano-3-(2-methyl-2H-pyrazol-3-ylamino)-acrylic acid ethyl ester 
• 168976-57-6 2-Ethyl-5-methyl-4-nitro-2H-pyrazole-3-carboxylic acid (2-methyl-2H-pyrazol-3-yl)-amide 
• 37799-77-2 diethyl 2-[(1-methyl-1H-pyrazol-5-ylamino)methylene]malonate 
• 849470-71-9 C₂₀H₂₂FN₅O₂ 
• 57861-03-7 2-((1-methyl-1H-pyrazol-5-yl)amino)benzoic acid 
• 19868-85-0 1-methyl-4-nitro-1H-pyrazol-5-amine 
• 1123178-02-8 1-(5-(5-(4-methoxyphenyl)pyrimidin-2-ylamino)-2-methylpyridin-3-yl)-3-(1-methyl-1H-pyrazo1-5-yl)urea 
• 1224886-72-9 2-({5-chloro-2-[(1-methyl-1H-pyrazol-5-yl)amino]-4-pyridinyl}amino)-N-methylbenzamide hydrochloride 
• 1227416-22-9 2-chloro-N-(1-methyl-1H-pyrazol-5-yl)-6-((7-oxo-2-phenyl-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidin-5-yl)methoxy)benzamide 
• 1246847-15-3 ethyl 6-(4-bromophenyl)-1-methyl-pyrazolo[3,4-b]pyridine-4-carboxylate 

Relevant academic research and scientific papers

The Formation of Seven-Membered Heterocycles under Mild Pictet-Spengler Conditions: A Route to Pyrazolo[3,4]benzodiazepines

Reported is a method for the synthesis of seven-membered heterocycles via a Pictet-Spengler condensation reaction under very mild conditions. High substrate scope allows for use of aldehydes using catalytic amounts of acetic acid yielding 39-90% and keton

Rearrangement of 1-Amino- and 1-Alkylamino-pyrazoles to 5-Aminopyrazoles

Rearrangement of 1-aminopyrazole and 1-alkylaminopyrazoles into the corresponding 5-aminopyrazoles has been achieved in 48percent aqueous hydrobromic acid.The reaction, occurring through a ring opening-ring closure mechanism, constitutes a new and unambiguous procedure for the preparation of 1-substituted 5-aminopyrazoles.The products have been identified on the basis of 1H and 13C n.m.r. spectroscopic results and comparison with authentic samples.

DYE MIXTURE AND METHOD FOR PRODUCING THE SAME, HAIR DYE, AND HAIR DYE SOLUTION

PROBLEM TO BE SOLVED: To provide a dye mixture which can prevent the deposition of a dye from aqueous solution and inhibits a change of hue due to mixture, and a method for producing the same, and a hair dye and hair dye solution comprising the dye mixture. SOLUTION: The present invention provides a dye mixture comprising a dye represented by formula (I) and (II), with the content of dye (II) being 0.001-5 mass% relative to the total content of dye (I) and (II) and a method for producing the same, and a hair dye and hair dye solution comprising the dye mixture (Me is a methyl group). SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

Investigation of pyrazolo-sulfonamides as putative small molecule oxytocin receptor agonists

The neuropeptide oxytocin has been implicated in multiple central nervous system functions in mammalian species. Increased levels have been reported to improve trust, alleviate symptoms related to autism and social phobias, and reduce social anxiety. Hoffman-La Roche published a patent claiming to have found potent small molecule oxytocin receptor agonists, smaller than the first non-peptide oxytocin agonist reported, WAY 267,464. We selected two of the more potent compounds from the patent and, in addition, created WAY 267,464 hybrid structures and determined their oxytocin and vasopressin receptor activity. Human embryonic kidney and Chinese hamster ovary cells were used for the expression of oxytocin or vasopressin 1a receptors and activity assessed via IP1 accumulation assays and calcium FLIPR assays. The results concluded that the reported compounds in the patent and the hybrid structures have no activity at the oxytocin or vasopressin 1a receptors.

Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives

The c-jun N-terminal kinase 3 (JNK3) is expressed primarily in the brain. Numerous reports have shown that inhibition of JNK3 is a promising strategy for treatment of neurodegeneration. The optimization of aminopyrazole-based JNK3 inhibitors with improved potency, isoform selectivity, and pharmacological properties by structure-activity relationship (SAR) studies utilizing biochemical and cell-based assays, and structure-based drug design is reported. These inhibitors had high selectivity over JNK1 and p38α, minimal cytotoxicity, potent inhibition of 6-OHDA-induced mitochondrial membrane potential dissipation and ROS generation, and good drug metabolism and pharmacokinetic (DMPK) properties for iv dosing. 26n was profiled against 464 kinases and was found to be highly selective hitting only seven kinases with >80% inhibition at 10 μM. Moreover, 26n showed good solubility, good brain penetration, and good DMPK properties. Finally, the crystal structure of 26k in complex with JNK3 was solved at 1.8 ? to explore the binding mode of aminopyrazole based JNK3 inhibitors.

Regiocontrolled synthesis of 3- and 5-aminopyrazoles, pyrazolo[3,4-d] pyrimidines, pyrazolo[3,4-b]pyridines and pyrazolo[3,4-b]quinolinones as MAPK inhibitors

Microwave irradiation of a hydrazine and 3-methoxyacrylonitrile, ethoxymethylenemalononitrile or ethyl acetoacetate provides rapid access to 3- or 5-substituted pyrazoles in excellent yield and with total regiocontrol in a process that can be switched from one regioisomer to the other by choice of conditions. Subsequent reaction, either by microwave-assisted hydrolysis and cyclocondensation with formamide, Hantzsch-type three-component reaction with an aldehyde and ketone, or by cyclocondensation with 2-nitrobenzaldehyde, provides the pyrazolo[3,4-d]pyrimidine, pyrazolo[3,4-b]pyridine or pyrazolo[3,4-b] quinolin-4-one framework, respectively, of inhibitors of mitogen-activated protein kinases.

The identification a novel, selective, non-steroidal, functional glucocorticoid receptor antagonist

The identification of novel, potent, non-steroidal/small molecule functional GR antagonist GSK1564023A selective over PR is described. Associated structure-activity relationships and the process of optimisation of an initial HTS hit are also described.

PYRIMIDINE AND PYRIDINE DERIVATIVES USEFUL AS HMG-COA REDUCTASE INHIBITORS AND METHOD OF PREPARATION THEREOF

Compounds are provided having the following structure which are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol

Rearrangement of N-(Alkylamino)azoles in Acid Media: A New Entry to C-Amino-N-substituted Azoles

A ring-opening / ring-closure mechanism for the thermal rearrangement of 1-(alkylamino)pyrazoles into 5-amino-1-alkylpyrazoles in acid medium has been established. 1-(Benzylamino)pyrazoles show a different reactivity, affording bis(5-amino-1-benzyl-4-pyrazolyl)phenylmethanes.The reaction was extended to 1-(alkylamino)indazoles but failed in the case of 1-(alkylamino)-1,2,4-triazoles.